Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
Body unavailable. Use the original source.
Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.